Loading…
Stoke Therapeutics, Inc. is projected to rise to $38.80 by 2027, a +29% move from its current price of $30.04. STOK is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/31/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 1 | $29.44 | $30.05 | $30.67 | +0.04% |
| Aug 2 | $29.21 | $30.06 | $30.94 | +0.07% |
| Aug 3 | $29.03 | $30.07 | $31.15 | +0.11% |
| Aug 4 | $28.88 | $30.08 | $31.34 | +0.14% |
| Aug 5 | $28.75 | $30.09 | $31.50 | +0.18% |
| Aug 6 | $28.64 | $30.10 | $31.65 | +0.21% |
| Aug 7 | $28.53 | $30.12 | $31.79 | +0.25% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $28.53 | $30.12 | $31.79 | +0.25% |
| Week 2 | $27.97 | $30.19 | $32.59 | +0.50% |
| Week 3 | $27.57 | $30.27 | $33.23 | +0.75% |
| Week 4 | $27.24 | $30.34 | $33.80 | +1.01% |
| Week 5 | $26.96 | $30.42 | $34.32 | +1.26% |
| Week 6 | $26.72 | $30.49 | $34.81 | +1.51% |
| Week 7 | $26.50 | $30.57 | $35.26 | +1.77% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Stoke Therapeutics, Inc. is a healthcare company that engages in the development of treatments for severe genetic diseases by upregulating protein expression. It uses its Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels.
Its lead product candidates include STK-002, which is in Phase 1 clinical trials for the treatment of autosomal dominant optic atrophy; and Zorevunersen (STK-001), an investigational new medicine for the treatment of Dravet syndrome being evaluated in Phase 3 clinical trials. The company also develops programs focused on various targets, including haploinsufficiency diseases of the central nervous system and eye. Stoke Therapeutics has a license and collaboration with Biogen Inc.
for the development and commercialization of zorevunersen for Dravet syndrome, and Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for genetic neurodevelopmental diseases. The company was formerly known as ASOthera Pharmaceuticals, Inc.
and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.
Stoke Therapeutics, Inc. (STOK) trades in the healthcare sector with a current price of $29.05 and a market cap of $1.81B. Its rank is 1978. The stock carries a bearish near-term tone but the long-range forecast shows rising value across multiple years, with progressively higher average prices and substantial upside potential in later years.
A major floor 17.1% below — a decisive break under it would weaken the trend.
The nearest floor, 7.9% below — buyers have tended to step in here.
The nearest ceiling, 9.9% above — a clean break opens room to run.
A major ceiling 24.1% above — clearing it would confirm fresh momentum.
Key STOK support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of STOK market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $29.50 | Buy | $29.58 | Buy |
| MA 10 | $29.17 | Buy | $29.57 | Buy |
| MA 20 | $30.21 | Sell | $29.89 | Buy |
| MA 50 | $30.33 | Sell | $30.61 | Sell |
| MA 100 | $32.06 | Sell | $31.02 | Sell |
| MA 200 | $31.66 | Sell | $29.34 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 49.66 | Neutral |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | -8.48 | Neutral |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 0.03 | Buy |
| ROC (12) | 3.12 | Buy |
| Bollinger %B (20,2) | 0.47 | Neutral |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | -0.20 | Sell |
| Awesome (5,34) | -0.98 | Sell |
| Ultimate (7,14,28) | 65.43 | Neutral |
| Momentum (10) | 0.93 | Buy |
| Aroon Osc (25) | -36.00 | Sell |
| Hull MA (9) | 29.73 | Buy |
| ADX (14) | 14.64 | Neutral |
| ATR (14) | 0.53 | Info |
The 30-day technical picture is bearish, with RSI14 at 40. The stock trades below its 50-day simple moving average of $30.80 and below its 200-day simple moving average of $31.56. Key near-term support sits at $28.48 and resistance at $33.02. The 30-day price range spans from $25.11 to $33.61, and the stock exhibits an annualized volatility of 40%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $27.68 | $30.04 | $40.13 | 0% | Neutral | |
| $31.66 | $38.80 | $49.82 | +29% | Bullish | |
| $37.70 | $47.17 | $62.34 | +57% | Bullish | |
| $40.94 | $52.09 | $70.44 | +73% | Bullish | |
| $45.67 | $58.98 | $81.31 | +96% | Bullish | |
| $46.81 | $61.26 | $85.88 | +104% | Bullish | |
| $47.60 | $63.07 | $89.78 | +110% | Bullish | |
| $57.08 | $76.51 | $110.42 | +155% | Bullish | |
| $65.31 | $88.49 | $129.35 | +195% | Bullish | |
| $70.52 | $96.56 | $142.82 | +221% | Bullish | |
| $97.95 | $140.48 | $218.42 | +368% | Bullish | |
| $167.28 | $259.26 | $433.94 | +763% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $27.68 | $30.04 | $34.97 | +0.00% |
| August 2026 | $25.67 | $29.97 | $35.68 | -0.24% |
| September 2026 | $26.42 | $31.04 | $37.33 | +3.56% |
| October 2026 | $26.72 | $31.54 | $38.24 | +1.62% |
| November 2026 | $26.63 | $31.57 | $38.52 | +0.09% |
| December 2026 | $27.48 | $32.69 | $40.13 | +3.56% |
Click any year to see its month-by-month STOK forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Stoke Therapeutics, Inc.'s 2026 outlook centres on $30.04, within a $27.68 to $40.13 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, STOK could reach as high as $49.82, with a base case around $38.80 and support toward $31.66 — roughly +29% from $30.04. Buyers look set to stay in control over this stretch.
Expect STOK to range from $37.70 to $62.34 through 2028. The $47.17 average target implies a +57% move from current prices. That is up +22% on the projected 2027 average. Momentum favours further upside here.
The STOK price prediction for 2029 points to an average of $52.09 (low $40.94, high $70.44) — a potential gain of +73% on today's $30.04. Buyers look set to stay in control over this stretch.
In 2030, STOK is projected to trade between $45.67 and $81.31, averaging $58.98 — a potential gain of +96% from today's $30.04. That is up +13% on the projected 2029 average. Momentum favours further upside here.
Stoke Therapeutics, Inc.'s 2031 outlook centres on $61.26, within a $46.81 to $85.88 range. That is up +4% on the projected 2030 average. That marks a +104% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, STOK could reach as high as $89.78, with a base case around $63.07 and support toward $47.60 — roughly +110% from $30.04. Momentum favours further upside here.
Expect STOK to range from $57.08 to $110.42 through 2033. The $76.51 average target implies a +155% move from current prices. That is up +21% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The STOK price prediction for 2034 points to an average of $88.49 (low $65.31, high $129.35) — a potential gain of +195% on today's $30.04. Momentum favours further upside here.
In 2035, STOK is projected to trade between $70.52 and $142.82, averaging $96.56 — a potential gain of +221% from today's $30.04. That is up +9% on the projected 2034 average. Buyers look set to stay in control over this stretch.
Stoke Therapeutics, Inc.'s 2040 outlook centres on $140.48, within a $97.95 to $218.42 range. That is up +45% on the projected 2035 average. That marks a +368% change versus current levels. Momentum favours further upside here.
By 2050, STOK could reach as high as $433.94, with a base case around $259.26 and support toward $167.28 — roughly +763% from $30.04. Buyers look set to stay in control over this stretch.
Investing $1,000 in STOK today (≈ 33.288948 STOK) could be worth
$8,630.48
+$7,630.48 (+763%) by 2050 · US Dollar
Based on the average projected STOK price of $259.26 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in STOKwould be worth at today's price.
$1,000 invested in STOK on Jul 30, 2025 (≈ 77.700078 STOK) would be worth
$2,334.11
+$1,334.11 (+133.4%) today · 2.33× · US Dollar
Based on a STOK entry price of $12.87 vs. today's $30.04.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $29.65 | $1,013.15 | +1.3% |
| 1 month ago | $32.72 | $918.09 | -8.2% |
| 3 months ago | $33.08 | $908.1 | -9.2% |
| 6 months ago | $30.34 | $990.11 | -1.0% |
| 1 year ago | $12.87 | $2,334.11 | +133.4% |
| All time (5.0y) ago | $28.86 | $1,040.89 | +4.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our STOK forecast.
Our base-case forecast reaches $60.00 around 2031.
Implied market cap at $60.00: $3.74B
The multi-year forecast depicts a bullish path from 2027 onward, with the average price rising from $35.74 in 2027 to $52.06 in 2030, and continuing higher to $203.81 average by 2050. Year-by-year highlights include 2030 avg $52.06 (ROI 79.2), 2035 avg $80.92 (ROI 178.5), 2040 avg $112.33 (ROI 286.7), and 2050 avg $203.81 (ROI 601.6). The forecast consistently flags bullish sentiment in the later years, indicating meaningful upside relative to the current level, while acknowledging the estimates may differ from actual outcomes.
Tap a question to reveal the answer.
2030 avg $52.06, min $39.88, max $72.76, ROI 79.2, sentiment BULLISH.
Forecast shows neutral in 2026 (avg $29.05) and bullish from 2027 onward, with increasing averages and ROIs (e.g., 2027 avg $35.74, ROI 23; 2030 avg $52.06, ROI 79.2; 2040 avg $112.33, ROI 286.7; 2050 avg $203.81, ROI 601.6). This indicates upside potential but is not a guarantee.
Yes in the forecast: max prices reach $110.56 in 2034, $121.89 in 2035, $178.41 in 2040, and $349.95 in 2050.
Current price is $29.05 and market cap is $1.81B.
2035 min $58.14, avg $80.92, max $121.89, ROI 178.5, sentiment BULLISH.
Stoke Therapeutics, Inc. Community Discussion
0Share your Stoke Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.